Tandem scFv-toxin Bispecific Fusion Protein

As a pioneer in bispecific antibody (BsAb) discovery and manufacture field, Creative Biolabs now provides a novel format of bispecific fusion proteins, tandem scFv-toxin.

Figure：Construction of tandem scFv-toxin (Leuk Res, 2009)

The tandem scFv-toxin, also known as bispecific ligand-directed toxin (BLT), is synthesized by fusing a truncated toxin with two well-established ligands. According to the strategy of immunotherapy, BLTs can show better activities than their monospecific counterparts because the two ligands can bind to their own specific receptors on the same cells simultaneously with increased total targeting capability, therefore the toxin portion can bind and kill target cells more effectively. Meanwhile, the catalytic toxins, such as pseudomonas exotoxin (PE) and diphtheria toxin (DT), are chosen because they can enter cytosol and induce cell death. Furthermore, we can mutate the key epitopic toxin regions in the truncated version of toxins genetically to overcome the inherent immunogenicity of toxins,

Targeted toxins can be an alternative therapy in antitumor treatment. Creative Biolabs is professional in generating tandem scFv-toxin bispecific fusion proteins with increased targeting capability and reduced immunogenicity, which can meet your specific requirements in scientific and clinical researches.

Reference

1. Daniel A. Vallera, et al. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res. 2009 Sep;33(9):1233-42.

For research use only. Not intended for any clinical use.